{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:28:38Z","timestamp":1792718918961,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejps.2021.105857","type":"journal-article","created":{"date-parts":[[2021,4,18]],"date-time":"2021-04-18T23:52:56Z","timestamp":1618789976000},"page":"105857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Novel water soluble sterile natamycin formulation (Natasol) for fungal keratitis"],"prefix":"10.1016","volume":"163","author":[{"given":"Thirumurthy","family":"Velpandian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayabalan","family":"Nirmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanuman P","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabanita","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2021.105857_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12281-013-0150-1","article-title":"Current Thoughts in Fungal Keratitis: Diagnosis and Treatment","volume":"7","author":"Ansari","year":"2013","journal-title":"Curr. Fungal Infect. Rep."},{"key":"10.1016\/j.ejps.2021.105857_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2007.05.012","article-title":"Cyclodextrins as pharmaceutical solubilizers","author":"Brewster","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.105857_bib0003","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1016\/S1473-3099(20)30448-5","article-title":"The global incidence and diagnosis of fungal keratitis","volume":"21","author":"Brown","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejps.2021.105857_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/jps.21312","article-title":"Preparation and characterisation of natamycin: \u03b3-cyclodextrin inclusion complex and its evaluation in vaginal mucoadhesive formulations","author":"Cevher","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105857_bib0005","article-title":"An update on cyclodextrins as drug vehicles for antimicrobial applications","author":"ELEFTHERIADOU","year":"2020","journal-title":"J. Pharm. Technolgy."},{"key":"10.1016\/j.ejps.2021.105857_bib0006","unstructured":"HMDB, 2021. Showing metabocard for Natamycin (HMDB0014964) [WWW Document]. URL https:\/\/hmdb.ca\/metabolites\/HMDB0014964 2021."},{"key":"10.1016\/j.ejps.2021.105857_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2015.11.016","article-title":"Cyclodextrins in pharmaceutical formulations II: Solubilization, binding constant, and complexation efficiency","author":"Jambhekar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2021.105857_bib0008","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1081\/DDC-120003445","article-title":"Ocular Preparations: The Formulation Approach","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2021.105857_bib0009","doi-asserted-by":"crossref","DOI":"10.4103\/ijo.IJO_378_19","article-title":"Intrastromal voriconazole: An adjuvant approach for recalcitrant mycotic keratitis","author":"Konar","year":"2020","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.ejps.2021.105857_bib0010","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1021\/jf030332y","article-title":"Formation of Natamycin:Cyclodextrin Inclusion Complexes and Their Characterization","volume":"51","author":"Koontz","year":"2003","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejps.2021.105857_bib0011","doi-asserted-by":"crossref","first-page":"7111","DOI":"10.1021\/jf030333q","article-title":"Stability of natamycin and its cyclodextrin inclusion complexes in aqueous solution","volume":"51","author":"Koontz","year":"2003","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejps.2021.105857_bib0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/jop.1986.2.67","article-title":"Topical ocular drug delivery: recent developments and future challenges","volume":"2","author":"Lee","year":"1986","journal-title":"J. Ocul. Pharmacol."},{"key":"10.1016\/j.ejps.2021.105857_bib0013","doi-asserted-by":"crossref","DOI":"10.2165\/00137696-200402040-00006","article-title":"Role of cyclodextrins in improving oral drug delivery","author":"Loftsson","year":"2004","journal-title":"Am. J. Drug Deliv."},{"key":"10.1016\/j.ejps.2021.105857_bib0014","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1590\/S0004-27492013000100016","article-title":"[Fungal keratitis: review of diagnosis and treatment]","volume":"76","author":"Mellado","year":"2013","journal-title":"Arq. Bras. Oftalmol."},{"key":"10.1016\/j.ejps.2021.105857_bib0015","doi-asserted-by":"crossref","DOI":"10.1089\/jop.2014.0004","article-title":"Safety and efficacy of intrastromal injection of 5% natamycin in experimental fusarium keratitis","author":"Mimouni","year":"2014","journal-title":"J. Ocul. Pharmacol.Ther."},{"key":"10.1016\/j.ejps.2021.105857_bib0016","doi-asserted-by":"crossref","DOI":"10.2147\/OPTH.S135112","article-title":"Combined intrastromal injection of amphotericin B and topical fluconazole in the treatment of resistant cases of keratomycosis: A retrospective study","author":"Nada","year":"2017","journal-title":"Clin.Ophthalmol."},{"key":"10.1016\/j.ejps.2021.105857_bib0017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jfo.2011.04.013","article-title":"A relevant choice for corticoid eye drops: solution or suspension?","volume":"34","author":"Nourry","year":"2011","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.ejps.2021.105857_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22010115","article-title":"Tedizolid-Cyclodextrin System as Delayed-Release Drug Delivery with Antibacterial Activity","volume":"22","author":"Paczkowska-Walendowska","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2021.105857_bib0019","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/ICL.0b013e31827a7a07","article-title":"In vitro uptake and release of natamycin from conventional and silicone hydrogel contact lens materials","volume":"39","author":"Phan","year":"2013","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.ejps.2021.105857_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2008.02.023","article-title":"Evaluation of Intrastromal Injection of Voriconazole as a Therapeutic Adjunctive for the Management of Deep Recalcitrant Fungal Keratitis","author":"Prakash","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2021.105857_bib0021","first-page":"597","article-title":"Natamycin in the treatment of fungal keratitis: a systematic review and Meta-analysis","volume":"8","author":"Qiu","year":"2015","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.ejps.2021.105857_bib0022","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0378-5173(86)90113-4","article-title":"A study of the inclusion complex of amphotericin-B with \u03b3-cyclodextrin","volume":"29","author":"Rajagopalan","year":"1986","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105857_bib0023","article-title":"Cyclodextrins as drug carrier molecule: A review","author":"Rasheed","year":"2008","journal-title":"Sci. Pharm."},{"key":"10.1016\/j.ejps.2021.105857_bib0024","series-title":"Handbook of Pharmaceutical Excipients: Pharmaceutical Excipients","author":"Rowe","year":"2012"},{"key":"10.1016\/j.ejps.2021.105857_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules23051161","article-title":"Solubility of Cyclodextrins and Drug\/Cyclodextrin Complexes","volume":"23","author":"Saokham","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejps.2021.105857_bib0026","doi-asserted-by":"crossref","first-page":"259","DOI":"10.7164\/antibiotics.25.259","article-title":"Polyene macrolide derivatives. II. Physical-chemical properties of polyene macrolide esters and their water soluble salts","volume":"25","author":"Schaffner","year":"1972","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejps.2021.105857_bib0027","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jps.2600690407","article-title":"Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits","volume":"69","author":"Schoenwald","year":"1980","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105857_bib0028","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejps.2017.12.027","article-title":"Involvement of nucleoside transporters in the transcorneal permeation of topically instilled substrates in rabbits in-vivo","volume":"114","author":"Sharma","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105857_bib0029","doi-asserted-by":"crossref","DOI":"10.1097\/ICO.0000000000001781","article-title":"Management Algorithm for Fungal Keratitis: The TST (Topical, Systemic, and Targeted Therapy) Protocol","author":"Sharma","year":"2019","journal-title":"Cornea"},{"key":"10.1016\/j.ejps.2021.105857_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jps.2600640606","article-title":"Vehicle effects on ocular drug bioavailability i: evaluation of fluorometholone","volume":"64","author":"Sieg","year":"1975","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2021.105857_bib0031","article-title":"Global data on visual impairments 2010","year":"2012","journal-title":"World Heal. Organ."},{"key":"10.1016\/j.ejps.2021.105857_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0167961","article-title":"Voriconazole Composited Polyvinyl Alcohol\/Hydroxypropyl-\u03b2-Cyclodextrin Nanofibers for Ophthalmic Delivery","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2021.105857_bib0033","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.16.4.730-797.2003","article-title":"Current Perspectives on Ophthalmic Mycoses","author":"Thomas","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejps.2021.105857_bib0034","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2021.105857_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2018.12.005","article-title":"Improving therapeutic efficacy of voriconazole against fungal keratitis: Thermo-sensitive in situ gels as ophthalmic drug carriers","author":"\u00dcst\u00fcnda\u011f Okur","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejps.2021.105857_bib0036","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0378-5173(91)90099-A","article-title":"Stability and in vitro activity of nystatin and its \u03b3-cyclodextrin complex against Candida albicans","volume":"73","author":"van Doorne","year":"1991","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2021.105857_bib0037","doi-asserted-by":"crossref","DOI":"10.1517\/17425240902798119","article-title":"Intraocular penetration of antimicrobial agents in ophthalmic infections and drug delivery strategies","author":"Velpandian","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2021.105857_bib0038","unstructured":"World Health Organisation (WHO), 2018. Priority eye diseases:Corneal opacities [WWW Document]. URL http:\/\/www.who.int\/blindness\/causes\/priority\/en\/index8.html (accessed 5.18.18)."},{"key":"10.1016\/j.ejps.2021.105857_bib0039","series-title":"World report on vision","year":"2019"},{"key":"10.1016\/j.ejps.2021.105857_bib0040","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/bjo.85.9.1070","article-title":"Treatment of fungal keratitis by penetrating keratoplasty","volume":"85","author":"Xie","year":"2001","journal-title":"Br. J. Ophthalmol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098721001597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:58:34Z","timestamp":1760529514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098721001597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":40,"alternative-id":["S0928098721001597"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105857","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel water soluble sterile natamycin formulation (Natasol) for fungal keratitis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2021.105857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105857"}}